Raltegravir

Raltegravir is an antiretroviral medication used in the treatment of Human Immunodeficiency Virus (HIV) infection. It is specifically classified as an integrase strand transfer inhibitor (INSTI), which means it works by inhibiting the HIV integrase enzyme, preventing the virus from integrating its genetic material into the host’s DNA. This, in turn, inhibits the replication of the virus, thus reducing the viral load in the body.
Raltegravir is often prescribed as part of a combination therapy for HIV-1 infection in adults and children above the age of 12, particularly for those who have experienced treatment failure with other antiretroviral medications. It is also used in post-exposure prophylaxis (PEP) to prevent HIV infection in individuals who have been exposed to the virus through high-risk encounters.
Raltegravir is available in tablet form, with the recommended dosage typically being 800mg twice daily. Adhere to the prescribed treatment regimen and schedule to achieve optimal therapeutic outcomes and to minimize the risk of developing drug-resistant strains of the virus.
Raltegravir does not cure HIV, but rather helps to manage the infection and improve the quality of life for those living with the condition. As with any antiretroviral medication, undergo regular monitoring and follow-up appointments with healthcare professionals to ensure the treatment is effective and to detect any potential side effects or drug interactions.